Delaware Clinical and Translational Research ACCEL Program

摘要--总体 该提案是临床和转译研究IDEA计划基础设施的竞争性更新 (IDEA-CTR)(U54)赠款最初于2013年9月授予。该项目名为特拉华州CTR Accel 在本申请提出时，该计划目前已经完成了四年的资助。该计划的总体目标 Accel计划仍将提供关键组件，以实现战略领域的增长，以改善 特拉华州的公民和全国人民。我们的财团目前由四个合作伙伴组成：特拉华大学 (Ud)--牵头机构；A.I.杜邦儿童医院，内穆尔儿童保健系统的一部分。 ；特拉华州最大的医疗保健系统克里斯蒂娜护理医院系统(CCHS)；以及 南卡罗来纳医科大学(MUSC)，我们的州外创意合作伙伴。在这场竞争性的更新中，我们将 扩大我们的联盟，将特拉华州立大学(DSU)包括在内，这是一所美国历史上的黑人公立大学- 大学位于特拉华州的多佛市。特拉华州是CTR拨款的理想州，因为它代表着整个美国 紧凑的形式。特拉华州的人口(约950,000人)反映了美国人口的城乡公民比率和 种族/种族多样性，22%的非裔美国人，69%的高加索人，8%的西班牙人，3%的亚洲人和1%的土著美国人。 成人(CCHS)和儿科(Nemour)医院系统占主导地位，为至少85%的居民提供服务 提供了一个独特的机会，将特拉华州作为检验医疗保健如何 变化可能会影响人口健康。与Accel计划目前享有的大力支持类似，该部分- 工程机构和州政府再次同意提供超过830万美元的资金，以支持Accel相关活动- 领带。在此次竞争续约中，Accel计划的结构和活动进行了修改。《Accel》 该计划现在只包括行政核心和五项必需的关键组成部分活动。此外, 在总结经验教训、发现机遇、取得成功的基础上，我们实现了令人振奋的重大变革 Accel计划的每一个组件。Accel计划的总体具体目标是：1)提供运营- 机会和基础设施，增强优秀调查人员进行令人兴奋和有影响力的工作的能力 需要和机会领域的临床和转化性研究计划。2)招聘、培训和发展诊所- CIAN、科学家和工程师，他们将发展创新、竞争、跨学科和跨机构的联系- 医学和翻译研究团队，以及3)扩展和加强模式社区参与外展研究 与国家和其他利益攸关方合作的计划，以促进不同人口的健康和福祉 特拉华州人。 Accel计划的领导层为我们在过去四年中创建的强大基础感到自豪 并期待着继续发展临床和翻译研究计划，以解决一些 特拉华州人和所有美国人最重要的医疗保健需求。

Abstract—Overall This proposal is a competitive renewal of the IDeA Program Infrastructure for Clinical and Translational Research (IDeA-CTR)(U54) grant originally awarded in September 2013. The program, titled the Delaware CTR ACCEL Program, has thus currently completed four years of funding at the time of this application. The overall goal of the ACCEL Program remains to provide the key components to allow growth in strategic areas to improve the health of the citizens of Delaware and the nation. Our consortium currently consists of four partners: University of Delaware (UD)—the lead institution; A.I. DuPont Hospital for Children, a part of the Nemours Children’s Health System (Ne- mours); Christiana Care Hospital System (CCHS), the largest health care sys-tem in the state of Delaware; and the Medical University of South Carolina (MUSC), our out-of-state IDeA partner. In this competitive renewal, we will expand our consortium to include Delaware State University (DSU), an American historically black, public univer- sity located in Dover, Delaware. Delaware is an ideal state for a CTR grant as it represents the whole of the USA in a compact form. The population of Delaware (~950,000) mirrors the US population in urban-to-rural citizen ratio and ethnic/racial diversity, with 22% African American, 69% Caucasian, 8% Hispanic, 3% Asian and 1% Native American. The dominance of adult (CCHS) and pediatric (Nemours) hospital systems, which serve at least 85% of the residents of the state, provides a unique opportunity to treat the state of Delaware as a model for examining how healthcare changes can impact population health. Similar to the strong support the ACCEL Program currently enjoys, the part- nering institutions and the State have again agreed to provide over $8.3 M in funds to support ACCEL related activi- ties. The structure and activities of the ACCEL Program have been modified in this competitive renewal. The ACCEL Program now only includes the Administrative Core and the five required key component activities. In addition, based on lessons learned, opportunities discovered, and success achieved, we have made substantive exciting changes to every component of the ACCEL Program. The Overall Specific Aims for the ACCEL Program are to: 1) Provide op- portunities and infrastructure that enhance the ability of outstanding investigators to conduct exciting and impactful clinical and translational research programs in areas of need and opportunity. 2) Recruit, train, and develop clini- cians, scientists, and engineers who will develop innovative, competitive, interdisciplinary, and interinstitutional clin- ical and translational research teams, and 3) Expand and enhance model community engagement outreach research programs that work with the State and other stakeholders to promote health and wellness to a diverse population of Delawareans. The leadership of the ACCEL program is proud of the strong foundation we have created over the past four years and looks forward to continuing to grow clinical and translational research programs that address some of the most important health care needs of Delawareans and all Americans.